It was recently reported that the human CD109 gene encodes a glycosyl-phosphatidylinositol-anchored glycoprotein that is a member of the a 2 -macroglobulin/C3, C4, C5 family of thioester-containing proteins. In this study, we found that the expression of mouse CD109 gene was upregulated in NIH3T3 cells expressing RET tyrosine kinase with a multiple endocrine neoplasia 2B mutation. Northern blot analysis showed a high level of expression of the CD109 gene only in the testis in normal human and mouse tissues. In addition, its expression was high in some human tumor cell lines, which included squamous cell carcinoma and glioblastoma cell lines, whereas it was undetectable in neuroblastoma and small-cell lung carcinoma cell lines. When CD109 expression was examined in 33 cases of human lung cell carcinomas by quantitative RT-PCR, a significant high expression of CD109 was detected in about half of squamous cell carcinomas examined, but not in adenocarcinoma, large-cell carcinoma and small-cell carcinoma. Similarly, upregulation of CD109 was observed in nine out of 17 esophageal squamous cell carcinomas. Thus, these results suggested that CD109 might be a useful molecular target for the development of new therapeutics for malignant tumors, such as squamous cell carcinoma.
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By differential display, we detected a transcript that was upregulated in NIH-RET(MEN2B) cells (Figure 1a and b). Using its cDNA fragment, we screened a cDNA library constructed from RNA of NIH-RET(MEN2B) cells and obtained a cDNA clone of 4717 base pairs in length that contained a 4329 bp open reading frame. It encoded a protein of 1442 amino acids with an aminoterminal signal peptide of 22 amino acids and a carboxyl-terminal hydrophobic glycosyl-phosphatidylinositol (GPI)-anchored cleavage-addition site (Figure 1c ). In addition, a sequence for the thioester bond (CGEQ) was found (amino acids 923-926 in Figure 1c ) (Hofmann et al., 1999) . After completing the sequence, it turned out that this cDNA encoded a mouse orthologue of the human CD109 gene, a member of the a 2 -macroglobulin/C3, C4, C5 family that was recently reported (Lin et al., 2002) .
To confirm that mouse CD109 is a GPI-anchored cell surface protein, COS7 cells were transfected with FLAG-tagged mouse CD109 cDNA cloned into an expression vector. Western blot analysis revealed that the transfectant expressed a protein of 180 kDa detected by an anti-FLAG monoclonal antibody that was the expected molecular mass of a FLAG-tagged CD109 fusion protein ( Figure 2a ). As shown in Figure 2b , its cell surface expression was observed by immunostaining with an anti-FLAG antibody. In addition, when the transfectant was treated with phosphatidylinositolspecific phospholipase C (PI-PLC) that cleaves the GPI anchor, the CD109 expression on the cell surface became almost undetectable (Figure 2c ), confirming that mouse CD109 is a GPI-anchored cell surface protein.
When CD109 gene expression was examined in various human and mouse adult tissues by Northern blotting, a high level of expression was detected only in the testis (Figure 3a and b). A 5.5 kb mRNA was a main transcript, although a low level of 10 kb transcript was also detected. To see whether upregulation of CD109 gene is observed in human tumors, we next investigated the CD109 expression in 30 human tumor cell lines. As shown in Figure 3c , it was highly expressed in glioblastoma and squamous cell carcinoma cell lines as well as in some adenocarcinoma and sarcoma (osteosarcoma and melanoma) cell lines. In contrast, its expression was very low and undetectable in the examined neuroblastoma, small-cell lung carcinoma, and leukemia/lymphoma cell lines.
CD109 expression was further analysed in human cancer tissues that were surgically resected. In total, 33 of lung carcinomas (14 adenocarcinomas, 11 squamous cell carcinomas, five large-cell carcinomas and three small-cell carcinomas) were examined by quantitative real-time RT-PCR. An average of expression level of Figure 1 Expression and amino-acid sequence of mouse CD109 gene. (a) Detection of a mouse CD109 cDNA fragment by differential display analysis. Total RNAs from NIH 3T3, NIH-RET(MEN2A) and NIH-RET(MEN2B) cells were analysed by differential display (Watanabe et al., 2002) . An arrowhead indicates a cDNA band derived from RNA of NIH-RET(MEN2B) cells that encodes mouse CD109. (b) Upregulation of CD109 mRNA in NIH-RET(MEN2B) cells. Total RNAs (20 mg) from NIH 3T3, NIH-RET(MEN2A) and NIH-RET(MEN2B) cells were analysed by Northern blotting with a CD109 cDNA fragment isolated by differential display. A 5.5 kb CD109 transcript was expressed at a high level in NIH-RET(MEN2B) cells (upper panel). An arrowhead indicates the location of 28S ribosomal RNA. The same membrane was rehybridized with glyceraldehyde-3-phophate dehydrogenase (GAPDH) cDNA as a control (lower panel). (c) Amino-acid sequences of mouse and human CD109. Identical amino acids between human and mouse sequences are shaded. The amino-terminal signal sequence (underlined), the thioester signature sequence (double underlined) and the GPI anchor cleavage-addition site (closed triangle) are shown CD109 expression in human cancer M Hashimoto et al the CD109 gene was significantly higher in squamous cell carcinoma than in adenocarcinoma, large-cell carcinoma, and small-cell carcinoma (Figure 4a ). Upregulation of CD109 expression (more than 2.5-fold than the control level) was observed in six out of 11 squamous cell carcinomas examined.
Moreover, we investigated the CD109 gene expression in esophageal squamous cell carcinomas. The expression levels were compared between 17 cases of human esophageal squamous cell carcinomas and seven cases of normal esophageal mucosae adjacent to carcinomas. Upregulation of CD109 expression (more than 2.5-fold than the average in normal mucosa) was detected in eight cases of carcinomas. In contrast, when its expression was examined in nine cases of gastric adenocarcinomas, only one case showed more than 2.5-fold upregulation of CD109. The elevated levels of CD109 expression did not correlate with the disease stages of the examined lung and esophageal squamous cell carcinomas (data not shown).
In the current study, we cloned the mouse CD109 gene by differential display analysis that was highly expressed in NIH(RET-MEN2B) cells. Lin et al. (2002) recently reported the cloning of human CD109 gene that encodes a novel member of the a 2 -macroglobulin/C3, C4, C5 family, including a 2 -macroglobulin-like protease inhibitors and complement proteins. The amino-acid identity between human and mouse genes was approximately 69%. Based on the amino-acid sequence, it turned out that CD109 is closely related to a 2 -macroglobulin-like protease inhibitors and more distantly related to C3 and C4 proteins (Lin et al., 2002) , although its physiological function still remains unknown. Human CD109 is a monomeric glycoprotein of 170 kDa that contains several N-linked endoglycosidase H-sensitive hybrid-type glycans, but no O-linked glycans, and is susceptible to cleavage with PI-PLC, indicating that CD109 is a GPI-anchored cell surface protein (Sutherland et al., 1991; Haregewoin et al., 1994; Smith et al., 1995; Solomon et al., 1998) . We confirmed by immunofluorescence and FACS analyses that mouse CD109 is expressed as a GPI-anchored cell surface protein that is cleaved by PI-PLC. 6 COS7 cells transfected with FLA-tagged mouse CD109 gene were incubated with 1 U/ml PI-PLC (generously provided by R Taguchi, Nagoya City University, Nagoya, Japan) for 1 h at 371C and washed with PBS containing 5% FBS. The cells were incubated for 60 min at 41C with an anti-FLAG M2 monoclonal antibody, followed by incubation with a FITC-conjugated secondary antibody for 60 min at 41C. After washing twice, the cells were suspended in PBS and analysed with FACSCalibur (Becton Dickinson) to investigate the amount of Flag-tagged mouse CD109 expression on the cell surface CD109 expression in human cancer M Hashimoto et al
To date, the expression of CD109 has been extensively studied in hematopoietic cells and detected in a subset of fetal and adult CD34 þ bone marrow mononuclear cells (Sutherland et al., 1991; Yeo, 1995, 1998; Rappold et al., 1997; Murray et al., 1999) . As almost all myelo-erythroid and megakaryoblastic progenitors are found in the CD34 þ /CD109 þ subset, but not in the CD34 þ /CD109 À subset, (Yeo and Sutherland, 1992) , this suggested that the most primitive hematopoietic stem cells might be present within the CD109 þ subset. In contrast, its expression became undetectable on mature blood cells. In this study, we showed that a high level of expression was detected only in the testis among various human and mouse adult tissues, indicating that a population of CD109 þ cells was very small in most normal tissues.
The finding that CD109 was upregulated in NIH 3T3 cell transformed by RET with a MEN2B mutation prompted us to investigate CD109 expression in tumor cells. As a result, we found that part of the human carcinoma and sarcoma cell lines, such as glioblastoma and squamous cell carcinoma cell lines, expressed CD109 at high levels, suggesting that CD109 may have the characteristics of a cancer-testis antigen. Moreover, to see whether CD109 expression is specific to certain cell types, we investigated its expression in lung, esophagus and gastric carcinomas by quantitative realtime RT-PCR. Interestingly, half of the lung squamous cell carcinomas showed significant high levels of CD109 expression as compared with adenocarcinomas, largecell carcinomas, and small-cell carcinomas. In addition, CD109 expression was upregulated in about 50% of the esophageal squamous cell carcinomas, but only in one case of gastric adenocarcinomas examined. Since normal esophageal mucosa showed low levels of CD109 expression, malignant transformation of squamous cells appeared to induce the upregulation of CD109 expression. Thus, CD109 expressed on the cell surface may become a useful molecular target to develop new therapeutics for malignant tumors, especially squamous cell carcinomas. . C: normal esophageal mucosae that were removed from the squamous cell carcinoma patients. The expression levels of CD109 in each sample (closed circles) are expressed as fold-induction of the average value of the control that was set at 1.0. Each value represents an average of at least three experiments. Open circles represent the average values of CD109 expression in each histological type of tumors and controls. Some closed circles include two cases that showed nearly identical values. The method employed is as follows: total RNAs were extracted from fresh-frozen tissues using the RNeasy Mini Kit and treated with RNase-free DNase I (Qiagen). cDNA synthesis was performed using the TaqMan Reverse Transcription kit (Applied Biosystems). Total RNA (200 ng) was reverse-transcribed in 10 ml of RT buffer consisting of 5.5 mM MgCl 2 , 2.5 mM random hexamers, 4 U RNase inhibitor, and 31.25 U MultiScribe Reverse Transcriptase with the following three-step incubations; 251C for 10 min, 371C for 60 min, and 951C for 5 min. Thermal cycling and fluorescent monitoring were performed using the ABI PRISM 7500 Sequence Detection System (Applied Biosystems). Intronspanning primers for the human CD109 gene and 18S ribosomal RNA (rRNA) gene were designed as follows: CD109 forward, 5 0 -AGATGATCTCAATCATGTGG-3 0 ; CD109 reverse, 5 0 -ACACTGAAGCATCTTGGG-3 0 ; 18S rRNA forward, 5 0 -AATCAGGGTTC-GATTCCGGA-3 0 ; 18S rRNA reverse, 5 0 -CCAAGATCCAACTACGAGCT-3 0 . PCR was carried out using 12.5 ml of 2 Â SYBR Green PCR master mix (Applied Biosystems) containing 5 mM forward primer and 5 mM reverse primer in a final volume of 25 ml. The PCR conditions were as follows: 951C for 10 min and 50 cycles of 951C for 30 s, 561C for 30 s, and 721C for 30 s
